Background: Treatment with intravenous alteplase for eligible patients with acute ischemic stroke is underused, with variation in treatment rates across the UK. This study sought to elucidate factors influencing variation in clinicians' decision-making about this thrombolytic treatment.
Introduction
Stroke remains a leading cause of death and disability. 1 Thrombolysis with recombinant tissue plasminogen activator (intravenous (IV) alteplase) is a cost-effective treatment for acute ischemic stroke that reduces strokerelated disability, but unwarranted variation exists in UK thrombolysis rates 2 despite a strong evidence base 3, 4 reflected in the National Stroke Strategy, National Institute for Health and Care Excellence (NICE) guidelines, 6 and treatment licensing criteria. 7 Since the expansion of 24/7 hyper-acute stroke services, organizational factors seem less likely to explain this variation, which may be accounted for by variation in clinical decision-making, based on interpretation and understanding of clinical factors, and on characteristics of the individual decision-makers (such as experience, attitude towards risk). The study aimed to elucidate patient and clinician factors that influence clinicians' decision-making about the offer of IV alteplase to patients with acute ischemic stroke. Clinical decision-making about IV alteplase is complex. The time limited window for treatment (maximum 4.5 h since symptom onset) and the many clinical factors that might influence the balance between the risk and benefit for individual patients factor into this high stakes decision. 8 Earlier treatment is associated with better outcomes, yet there is a small but significant risk of adverse outcomes, mainly due to treatment-related symptomatic intracranial hemorrhage (sICH). 9 Decision-making is further complicated by uncertainty in research evidence, typically where high-quality data from randomized controlled trials do not exist regarding the suitability of certain patients for treatment with IV alteplase. 10 In order to understand the variation in treatment rates, 2 the lack of expert consensus on several treatment exclusion criteria, 11 and on-going debates regarding the efficacy of IV alteplase, 12 ,13 a research method is required that reflects decision-making in practice.
14 A discrete choice experiment (DCE) facilitates the investigation of multiple factors in a decision and is therefore appropriate for exploring this complex decision. This method enables the nuances of decision-making to be understood by providing insights not easily captured using more traditional research methods, such as interviews or observation. DCEs have been increasingly adopted to examine healthcare decision-making, including stroke rehabilitation. 15 Through a novel DCE approach, this study aimed to elucidate the factors influencing and contributing to variation in clinicians' decision-making about treating patients with acute ischemic stroke with IV alteplase, with a focus on areas of clinical uncertainty and borderline cases.
Methods

Study design
The DCE development process consisted of five iterative stages, informed by current good practice recommendations. [16] [17] [18] Through expert design and pilot testing, 19 hypothetical patient vignettes mimicked the clinical decision and required a binary response (offer IV alteplase or not). Supplementary Tables 1 and 2 describe factors and levels included in the study and their accompanying definitions. Optional free text boxes were included after each vignette for participants to comment on their decision-making, assisting with interpretation of findings (further design information and qualitative results methods can be found online as Supplementary material). A blocked design allowed a subset of vignettes to be presented to each participant to avoid overburdening participants (Figure 1 ).
An online survey also included questions and measurement scales to collect information on clinician characteristics that were hypothesized to influence decision-making, including demography and level of experience. A scale was developed to gauge the institutional culture with respect to thrombolysis (''Institutional Culture Scale,'' see Supplementary Table 3 ). The risk-taking sub-scale of the Jackson Personality Inventory (JPI) 20 and the Physician Reaction to Uncertainty Scale 21 were also employed. Clinicians were asked to state how recent their last thrombolysis decision was, and how many stroke patients they had treated with IV alteplase and how many were harmed as a result, in the past 12 months. Six-point Likert scales were used to assess the impact of clinicians' level of comfort treating a patient outside the licensing criteria and their views on the strength of the evidence base.
Ethical approval was obtained from Newcastle University Research Ethics Committee (reference: 00720/2013).
Recruitment
UK clinicians who were involved in decision-making regarding the offer of IV alteplase for patients with acute ischemic stroke were recruited via newsletters and emails sent through relevant professional associations, including the British Association of Stroke Physicians, Society for Acute Medicine, College of Emergency Medicine, British Geriatrics Society, and Association of British Neurologists. An invitation to participate was also sent to UK Safe Implementation of Treatments in Stroke (SITS) coordinators and information about the study was included on the Sentinel Stroke National Audit Programme (SSNAP) website. A screening question was first provided to participants ensuring they were involved in the ''final decisionmaking'' about thrombolysis. The survey was live for six months from September 2014.
Statistical analysis
Data were analyzed in STATA IC13. 22 Mixed logit regression (mixlogit) analyses were conducted to facilitate the examination of heterogeneity amongst respondents. The intercept (alternative specific International Journal of Stroke, 13 (1) constant; ASC) and model parameters were assumed to be random and normally distributed. A positive coefficient for a level of a factor in the mixlogit models, compared with the reference level of the factor, represents a driver of a decision to offer treatment with IV alteplase, whereas a negative coefficient represents an inhibiting influence on decisions to offer this treatment (i.e. more likely not to offer treatment). Significance was set at a P-value of <0.05, and the odds ratios (95% confidence intervals) were calculated to show magnitude/precision of effects in the regression models: patient-related factors (model 1) and both patient and clinician-related factors (model 2). Implausible combinations (e.g. pre-stroke dependency of mRS 1 and severe dementia) were omitted from the regression models. In addition, to control for the effects of block design, seven dummy variables were included in the analyses (comparing each design block to block 1). Table 1 presents a summary of the socio-demographic profile and other characteristics of respondents (N ¼ 138). Respondents had a mean age of 46 years (range: 30-68). The majority were male (73%) and stroke physicians (59%). The average experience treating stroke patients and administering intravenous alteplase was 11 years (range: 3 months-38 years) and 6 years 4 months (range: 3 months-22 years), respectively. Although no information is available about the non-respondents to the online survey, the profile of the respondents is broadly representative of the population of medical professionals involved in acute stroke care in the UK. Based on data from the SSNAP acute organisation audit, 23 the profile of the current sample in terms of medical specialty is proportionately representative of those involved in decision-making about treatment of acute stroke patients; stroke physicians are most often on thrombolysis rotas, followed in decreasing order by geriatricians, neurologists, accident and emergency (A&E) and acute medicine physicians. Furthermore, the average age and gender distribution in the current sample is consistent with data from the Royal College of Physicians (RCP) 2012 census. 24 Reliability analyses were conducted on the scales employed in the survey and showed good to high reliability across scales (Supplementary material). International Journal of Stroke, 13(1)
Results
Sample characteristics
There was overall general preference not to offer IV alteplase to patients described in the hypothetical vignettes, with 1103 decisions (68.6%) not to offer treatment with IV alteplase compared to 504 decisions to offer the treatment (31.4%). The standard deviation for the ASC was statistically significant suggesting considerable heterogeneity among respondents in decision-making. There was also substantial heterogeneity on several of the random effects coefficients, with nine standard deviations significant, indicating the variation between participants in their IV alteplase decisions as a function of differing levels of patient-related factors. Table 5 ). Model 2 added seven clinician characteristics to the patient-related factors: respondents' perception of the effectiveness and safety of treating acute ischemic stroke patients with IV alteplase; physician reaction to uncertainty scale; clinicians' attitude towards risk; estimated number of patients harmed by IV alteplase in the past 12 months and days since a patient was harmed; estimated number of patients treated with IV alteplase in the past 12 months; and comfort treating patients outside licensing criteria.
DCE regression results
Model 1 -Patient-related factors (Supplementary
The standard deviation for the ASC for Model 2 was also statistically significant, which indicates the presence of considerable heterogeneity among respondents regarding their decisions about treating patients with IV alteplase. There was considerable heterogeneity for the random effects coefficients (i.e. the levels of patient factors), with the standard deviations of 17 factor levels emerging as statistically significant. All the statistically significant patient factor predictors from Model 1 remained significant in Model 2, but two additional patient factors became statistically significant predictors of decisions to offer treatment with IV alteplase: moderate dementia; and NIHSS 5 with aphasia.
Respondents' were significantly more likely to offer treatment of IV alteplase when they perceived the evidence base for this treatment to be robust; had treated a high number of patients in the past 12 months; and reported a higher level of discomfort with uncertainty. Clinicians who reported being comfortable treating patients outside the licensing criteria were significantly less likely to offer thrombolysis.
Comparison of the Akaike and Bayesian information criteria established that Model 2 was a better fit for these data than Model 1.
The predicted probabilities of offering IV alteplase for patients with acute ischemic stroke based on Model 1 are presented in Supplementary Table 6 .
Discussion
This is the first DCE to explore patient and clinician factors that influence the decision to offer IV alteplase (thrombolysis) to treat patients with acute ischemic stroke, with a particular focus on areas of uncertainty and borderline cases. For the vignettes included in this study, analysis revealed an aggregate level preference not to offer this treatment, which was expected given that the vignettes were designed to explore decisions related to the ''gray'' areas of the licensing and evidence base for treatment. Levels of seven different patient-related factors (patient age, patient ethnicity, stroke symptom onset time, pre-stroke dependency, systolic blood pressure, stroke severity [NIHSS] 25 ; and pre-stroke cognitive status) and four different clinician-related ''psychosocial'' factors (perception of the evidence for the effectiveness and safety of IV alteplase, number of patients treated in the past 12 months, comfort with uncertainty, and comfort with treating patients outside the licensing criteria) were significant predictors of the treatment decision.
Patients aged 95 were significantly less likely to be offered treatment compared with patients aged 68. However, respondents were significantly more likely to treat 85 year olds compared with patients aged 68. The benefits of thrombolysis for older patients in terms of reduction in disability are at least as great as younger patients, despite an increased risk of symptomatic intracranial hemorrhage. This may also reflect the acceptance of a high profile clinical trial and casecontrol study data that reports benefit for patients aged >80, in particular for those with onset to treatment time of <3 h. 3, 4 It is feasible that a social desirability effect explains this latter finding; respondents may be over-compensating (pro-actively recommending a positive decision) to avoid denying treatment based on age. It appears that clinicians are not disinclined to treat older patients, but less likely to treat the very old ($95). This may reflect the upper limit of data from IST-3 or clinical experience (there are few patients who have been treated in this age range in routine practice). SITS data indicate that only approximately 10% of treated patients were older than 80 26 and national audit data suggest that only 2.5% of the total number of patients who received IV alteplase between April 2010 and November 2011 were older than 90 years. 27 Consistent with evidence of increased benefit with earlier treatment, 4 we identified a statistically significant decreased likelihood of offering treatment to patients who could be treated at 4 h 15 min compared to 50 min from symptom onset. However, clinicians were significantly more likely to treat patients at 2 h 30 min relative to 50 min. This unexpected finding suggests that some clinicians rarely see patients this soon after onset or that clinicians might observe cases presenting early for a short while, particularly if there are factors which create high uncertainty; for instance in mild stroke, when a patient's symptoms are rapidly improving, to see if symptoms may resolve (per licensing guidelines 7 ), or to give blood pressure time to stabilize or to take more readings before making a final decision. 28, 29 This is in contrast to research which confirms that earlier treatment is associated with substantially more favorable outcomes, 9 particularly when treatment occurs within the ''golden hour'' (<60 min from symptom onset). 29 Respondents were significantly more likely to offer IV alteplase to patients with moderate or severe stroke and not offer IV alteplase to patients with mild stroke. These findings are likely to reflect the lack of data and/ or uncertainty around the risk/benefit ratio of treatment of minor stroke and the otherwise poor outcomes for untreated patients with severe strokes. There was significant heterogeneity among respondents on the influence of NIHSS 2 with aphasia and NIHSS 5 without aphasia, implying that clinicians differ in their thresholds for treatment of minor stroke and may consider the gains in quality of life for individual patients with isolated language deficits differently.
Compared to white patients, Afro-Caribbean patients were significantly more likely to be offered treatment, though there was no effect for Asian ethnicity. The explanation for this finding is unclear.
Patients with pre-stroke dependency of mRS 3 were more likely to be offered treatment than those with mRS 4. We would have expected that respondents would be more willing to treat patients with mRS 1 compared to mRS 4, but this did not emerge. However, the failure of this to reach significance may be due to an imbalance between the levels of pre-stroke dependency across vignettes in the study, where mRS 1 vignettes were significantly underrepresented.
Patients presenting with severe dementia were significantly less likely to be offered IV alteplase in Models 1 and 2, although in Model 2, clinicians were more likely to offer treatment to those with moderate dementia (compared to patients with no memory problems). This is difficult to explain but may be due to an attempt to preserve a patients' independence when there is already a low probability that this might be retained. Inspection of the standard deviations reveals significant variation between respondents on the influence of both moderate and severe dementia on decisionmaking. This may show that clinicians are weighing up the pros and cons of treatment with reference to individual patient characteristics that are not part of the licensing criteria, although it may also reflect perceptions that dementia reduces likelihood of clinical benefit or is associated with an increased risk of adverse effects. However, current evidence suggests there is no increased risk of adverse effects from IV alteplase in patients with dementia. 30 Four of the seven clinician factors emerged as significant. There was a significant association found between the respondents' perception of the evidence International Journal of Stroke, 13 (1) base and the offer of treatment with IV alteplase. Greater discomfort with uncertainty was associated with increased likelihood of offering IV alteplase. This may indicate a preference for action over inaction in instances of high uncertainty, or what may be termed commission bias when observed consistently. 31 Commission bias is defined as the tendency towards action/intervention rather than inaction. 31 Given the high scores observed on the Institutional Culture Scale in the study (indicating a strong culture of administering IV alteplase to patients with acute ischemic stroke in respondents' institutions), clinicians may worry more about decisions not to treat and, therefore, those with higher levels of discomfort with uncertainty may be more willing to provide this treatment, if it is perceived as the dominant or favored position among colleagues. The results also indicated that clinicians who reported being more comfortable treating patients outside the licensing criteria were less likely to offer treatment in the current study; we do not have an explanation for this finding.
Finally, there was a significant positive association between clinicians' experience of administering IV alteplase and the likelihood of offering the treatment in the current study. This may indicate that familiarity with administration of the treatment (and positive outcomes) increases the likelihood of future use and has important practical implications for how clinicians are supported when they begin involvement in decision-making. 32 Alternatively, it may simply represent that those more likely to offer treatment in the DCE are more likely to offer treatment in practice, and therefore have higher reported treatment rates.
A key strength of this study was our ability to account for both observed heterogeneity among respondents (via inclusion of clinician factors in the model) as well as unobserved variation (via the estimation of random parameters for the alternative specific constant and factor levels) using the mixed logit regression. Our research offers an important contribution towards a deeper understanding of the factors influencing the decision to offer IV alteplase to patients, in particular factors that influence decisions for patients who fall within the licensing criteria ''gray'' zone. However, a limitation of the study was the potential for response bias, given we cannot be certain about the absolute number of eligible clinicians who received the invitation to participate.
There were a number of results in this study that were unexpected, for example, respondents were more likely to offer IV alteplase to patients presenting with a stroke onset time of 2 h 30 min compared to 50 min. We do not have clear explanations for these findings without undertaking additional data collection. There are at least three issues to consider: with IV alteplase involves a high degree of confidence that ischemic stroke is the cause of the acute symptoms. Despite assurance that only patients with acute ischemic stroke were being described in the vignettes, respondents may have been influenced by their clinical experience with stroke mimics. For instance, this may explain the apparent greater enthusiasm to treat at 2 h 30 min rather than 50 min, as respondents may have been concerned that the former could resolve and be a transient ischemic attack (TIA) rather than stroke. This may be a training issue which should be addressed.
Training for the assessment and treatment of patients with acute ischemic stroke should address the impact of the influence of clinician factors on decisionmaking, impart cognitive de-biasing strategies to optimize and support decision-making, and should ensure clinicians develop practical learning and self-efficacy in the administration of IV alteplase to eligible patients early in training to maximize appropriate treatment utilization. The use of patient vignettes as choice scenarios which focus on the ''gray'' areas in decisionmaking are useful in generating discussion and revealing differences in individual-level clinical decision-making. Future DCEs could feed back information to participants about their decision-making relative to other experienced colleagues, and inform reflective practice and professional development. High-quality clinical studies are also required to inform ''gray areas'' of decisionmaking and address current gaps in the evidence base; in particular, those patient factors (e.g. moderate and severe dementia) which resulted in significant heterogeneity in decision-making among participants in the current study. Future research could apply this method to make between-country comparisons of IV alteplase decision-making and should investigate additional factors beyond those included in this study. National stroke audit programs should consider including additional patient variables, such as pre-stroke cognitive status, in data collection strategies, as this could further illuminate variances in decision-making about the offer of IV alteplase.
